OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Gemma Reynolds, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin, et al.
Blood Advances (2023) Vol. 7, Iss. 19, pp. 5898-5903
Open Access | Times Cited: 49
Gemma Reynolds, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin, et al.
Blood Advances (2023) Vol. 7, Iss. 19, pp. 5898-5903
Open Access | Times Cited: 49
Showing 1-25 of 49 citing articles:
Multiple myeloma
Florent Malard, Paola Neri, Nizar J. Bahlis, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 48
Florent Malard, Paola Neri, Nizar J. Bahlis, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 48
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Meera Mohan, Jorge Monge, Nishi Shah, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 47
Meera Mohan, Jorge Monge, Nishi Shah, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 47
Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study
Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 6, pp. 764-771
Open Access | Times Cited: 18
Aurélie Jourdes, Elise Cellerin, Cyrille Touzeau, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 6, pp. 764-771
Open Access | Times Cited: 18
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos, et al.
Cancer (2023) Vol. 130, Iss. 6, pp. 886-900
Open Access | Times Cited: 32
Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos, et al.
Cancer (2023) Vol. 130, Iss. 6, pp. 886-900
Open Access | Times Cited: 32
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis
Gemma Reynolds, Marsali Maclean, Edward R. Scheffer Cliff, et al.
Blood Advances (2024) Vol. 8, Iss. 13, pp. 3555-3559
Open Access | Times Cited: 12
Gemma Reynolds, Marsali Maclean, Edward R. Scheffer Cliff, et al.
Blood Advances (2024) Vol. 8, Iss. 13, pp. 3555-3559
Open Access | Times Cited: 12
Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
Fahad Nashmi Alshammari, Abdullah M. Alrajhi, Jude Howaidi
Hematology (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Fahad Nashmi Alshammari, Abdullah M. Alrajhi, Jude Howaidi
Hematology (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 1
Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies
Ayrton Bangolo, Behzad Amoozgar, Charlene Mansour, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 282-282
Open Access | Times Cited: 1
Ayrton Bangolo, Behzad Amoozgar, Charlene Mansour, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 282-282
Open Access | Times Cited: 1
Advancements in Multiple Myeloma Therapies: A Comprehensive Review by Disease Stage
Hager Hisham El Khatib, Хамдан Абдулла, Layla Khaled Nassar, et al.
Lymphatics (2025) Vol. 3, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Hager Hisham El Khatib, Хамдан Абдулла, Layla Khaled Nassar, et al.
Lymphatics (2025) Vol. 3, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Karthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Karthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7
Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7
IgG replacement in multiple myeloma
Alex Wonnaparhown, Talal Hilal, Jacqueline D. Squire, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Alex Wonnaparhown, Talal Hilal, Jacqueline D. Squire, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
Darren Pan, Joshua Richter
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 6, pp. 237-245
Closed Access | Times Cited: 5
Darren Pan, Joshua Richter
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 6, pp. 237-245
Closed Access | Times Cited: 5
Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies
Hind Rafei, Katayoun Rezvani
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 764-766
Closed Access | Times Cited: 4
Hind Rafei, Katayoun Rezvani
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 764-766
Closed Access | Times Cited: 4
Diagnosis and management of bispecific T cell–engaging antibody toxicity: A primer for emergency physicians
Monica K. Wattana, Jonathan Rowland, Aiham Qdaisat, et al.
Cancer Treatment Reviews (2025), pp. 102889-102889
Closed Access
Monica K. Wattana, Jonathan Rowland, Aiham Qdaisat, et al.
Cancer Treatment Reviews (2025), pp. 102889-102889
Closed Access
Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma
Joshua Richter, Madhav V. Dhodapkar, Mengying Li, et al.
American Journal of Hematology (2025)
Closed Access
Joshua Richter, Madhav V. Dhodapkar, Mengying Li, et al.
American Journal of Hematology (2025)
Closed Access
Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies
Taekeun Park, S. Jang, Youngil Koh, et al.
Journal of Korean Medical Science (2025) Vol. 40
Open Access
Taekeun Park, S. Jang, Youngil Koh, et al.
Journal of Korean Medical Science (2025) Vol. 40
Open Access
Bispezifische Antikörper in der Therapie hämatologischer Neoplasien und solider Tumoren
Xiang Zhou, Johannes M. Waldschmidt, Hermann Einsele
Deleted Journal (2025)
Open Access
Xiang Zhou, Johannes M. Waldschmidt, Hermann Einsele
Deleted Journal (2025)
Open Access
Baicalin, Amoxicillin, and Probenecid Provide Protection in Mice Against Glaesserella parasuis Challenge
Jingyang Li, Ronghui Luo, Yunjian Fu, et al.
Biomolecules (2025) Vol. 15, Iss. 4, pp. 507-507
Open Access
Jingyang Li, Ronghui Luo, Yunjian Fu, et al.
Biomolecules (2025) Vol. 15, Iss. 4, pp. 507-507
Open Access
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
Meera Mohan, Anikó Szabó, Heloise Cheruvalath, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Meera Mohan, Anikó Szabó, Heloise Cheruvalath, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies
Michael D. Jain, Jeremy S. Abramson, Stephen M. Ansell
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Michael D. Jain, Jeremy S. Abramson, Stephen M. Ansell
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
Katia Mancuso, Marco Talarico, Enrica Manzato, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1514-1514
Open Access
Katia Mancuso, Marco Talarico, Enrica Manzato, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1514-1514
Open Access
Multiple myeloma and infections in the era of novel treatment modalities
Mobil Akhmedov, P. A. Zeynalovа, А. А. Феденко
Leukemia Research (2024) Vol. 143, pp. 107544-107544
Closed Access | Times Cited: 3
Mobil Akhmedov, P. A. Zeynalovа, А. А. Феденко
Leukemia Research (2024) Vol. 143, pp. 107544-107544
Closed Access | Times Cited: 3
Improving infection reporting in hematology treatment trials
Benjamin W. Teh, Gemma Reynolds, Małgorzata Mikulska, et al.
Blood Advances (2024) Vol. 8, Iss. 22, pp. 5925-5926
Closed Access | Times Cited: 3
Benjamin W. Teh, Gemma Reynolds, Małgorzata Mikulska, et al.
Blood Advances (2024) Vol. 8, Iss. 22, pp. 5925-5926
Closed Access | Times Cited: 3
